Clinical Trial

NS-050/NCNP-03 in Boys With DMD (Meteor50)

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.
Protocol Amendment History 1 change
notable Primary completion pushed: 2027-05 -> 2028-03 2026-06-17
Trial Details
NCT Number NCT06053814
Lead Sponsor NS Pharma, Inc.
Collaborators: Nippon Shinyaku Co., Ltd.
Conditions Duchenne Muscular Dystrophy
Enrollment 20 participants
Start Date 2024-09-18
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-16